Search - tctmd.com

Displaying 121 - 140 of 371

Sort: Relevancy | Date

News Conference News EuroPCR 2018

DCBs for CAD in Certain Patients With Large Vessel De Novo Disease? DEBUT Says Yes

Caitlin E. Cox

May 25, 2018

News Daily News

RANGER-SFA Data Support Another Paclitaxel-Coated Balloon for Superficial Femoral Artery Disease

L.A. McKeown

May 08, 2018

News Industry News

Medtronic IN.PACT(TM) Admiral(TM) Drug Coated Balloon Receives FDA Approval to Treat Long SFA Lesions

April 24, 2018

News Daily News

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

L.A. McKeown

February 11, 2018

News Industry News

SELUTION™ First-in-Man Study Achieves Primary Endpoint

January 31, 2018

News Conference News TCT 2017

DARE Supports Drug-Coated Balloon as Alternative to DES for Any In-Stent Restenosis

Todd Neale

October 30, 2017

News Industry News

Eurocor announces the presentation of the 12 months data of the Freeway Stent Study at CIRSE in Copenhagen

September 19, 2017

News Conference News VIVA 2017

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

L.A. McKeown

September 18, 2017

News Conference News VIVA 2017

DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease

L.A. McKeown

September 13, 2017

News Industry News

Medtronic IN.PACT Admiral DCB Global Two Year Data and IN.PACT SFA Four Year Data Presented in VIVA Late Breaking Clinical Trials

September 12, 2017

News Daily News

Registry Confirms Long-term Durability of Drug-Coated Balloon for Femoropopliteal Lesions

L.A. McKeown

August 03, 2017

News Industry News

Spectranetics Announces FDA Approval of Stellarex™ Drug-Coated Balloon

July 27, 2017

News Industry News

Spectranetics Announces FDA Approval of Stellarex™ Drug-Coated Balloon

July 26, 2017

News Industry News

TriReme Medical Reports Negative Late Lumen Loss At 24-Month Angiographic Follow-Up For Chocolate Heart™ Drug-Coated Coronary Balloon

June 22, 2017

News Daily News

Use of DAPT Score Following PCI Validated in PRODIGY Study

Yael L. Maxwell

June 12, 2017

News Industry News

STENTYS: Follow-Up of the APPOSITION IV and OPEN II Clinical Trials at Respectively 3 and 4 Years Confirms the Initial Positive Study Outcomes

May 25, 2017

News Daily News

10-Year Follow-up of Early DES Shows Steady Risk of Late Events

L.A. McKeown

February 08, 2017

News Conference News TCT 2016

ILLUMENATE: Low-Dose DCB Bests Angioplasty Alone in Complex Patients With SFA/Popliteal Lesions

L.A. McKeown

November 07, 2016

News Industry News

Zilver® PTX® with Thumbwheel Delivery System Launched in France

September 23, 2016

News Conference News VIVA 2016

Long PAD Lesions Respond Well to DCB, but Optimal Patient Selection Still Unclear

L.A. McKeown

September 21, 2016

Advertisement

DCBs for CAD in Certain Patients With Large Vessel De Novo Disease? DEBUT Says Yes

RANGER-SFA Data Support Another Paclitaxel-Coated Balloon for Superficial Femoral Artery Disease

Medtronic IN.PACT(TM) Admiral(TM) Drug Coated Balloon Receives FDA Approval to Treat Long SFA Lesions

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

SELUTION™ First-in-Man Study Achieves Primary Endpoint

DARE Supports Drug-Coated Balloon as Alternative to DES for Any In-Stent Restenosis

Eurocor announces the presentation of the 12 months data of the Freeway Stent Study at CIRSE in Copenhagen

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease

Medtronic IN.PACT Admiral DCB Global Two Year Data and IN.PACT SFA Four Year Data Presented in VIVA Late Breaking Clinical Trials

Registry Confirms Long-term Durability of Drug-Coated Balloon for Femoropopliteal Lesions

Spectranetics Announces FDA Approval of Stellarex™ Drug-Coated Balloon

Spectranetics Announces FDA Approval of Stellarex™ Drug-Coated Balloon

TriReme Medical Reports Negative Late Lumen Loss At 24-Month Angiographic Follow-Up For Chocolate Heart™ Drug-Coated Coronary Balloon

Use of DAPT Score Following PCI Validated in PRODIGY Study

STENTYS: Follow-Up of the APPOSITION IV and OPEN II Clinical Trials at Respectively 3 and 4 Years Confirms the Initial Positive Study Outcomes

10-Year Follow-up of Early DES Shows Steady Risk of Late Events

ILLUMENATE: Low-Dose DCB Bests Angioplasty Alone in Complex Patients With SFA/Popliteal Lesions

Zilver® PTX® with Thumbwheel Delivery System Launched in France

Long PAD Lesions Respond Well to DCB, but Optimal Patient Selection Still Unclear

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content